USPTO Awards Sanaria with the 2020 Patents for Humanity Award
USPTO awards Sanaria with the 2020 Patents for Humanity Award for Sanaria's malaria vaccine.
Sanaria Attended the 68th ASTMH Meeting
From 20-24 November 2010, Sanaria participated in the 68th Annual ASTMH (American Society of Tropical Medicine and Hygiene) Meeting held at the Gaylord Resort in Washington, D.C.
Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants
Abstract
In 2016, there were more cases and deaths caused by malaria globally than in 2015. An effective vaccine would be an ideal additional tool for reducing malaria’s impact. Sanaria® PfSPZ Vaccine, composed of radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) has been well tolerated and safe in malaria- na ̈ıve and experienced adults in the United States and Mali and protective against controlled human malaria infection with Pf in the United States and field transmission of Pf in Mali, but had not been assessed in younger age groups. We, therefore, evaluated PfSPZ Vaccine in 93 Tanzanians aged 45 years to 6 months |
Nature Magazine News: Promising malaria vaccine to be tested in first large field trial – Declan Butler
The vaccine can confer up to 100% protection and will be tested in 2,100 people on the west African island of Bioko.
